Skip to main content
Journal cover image

Safety and patient acceptability of intravenous immune globulin in 10% maltose.

Publication ,  Journal Article
Ochs, HD; Buckley, RH; Pirofsky, B; Fischer, SH; Rousell, RH; Anderson, CJ; Wedgwood, RJ
Published in: Lancet
November 29, 1980

The safety and patient acceptance of two preparations of modified (reduced and alkylated) immune globulin for intravenous use were evaluated; one preparation was formulated as a 5% solution in 10% maltose (IGIV-maltose), the other did not contain maltose (IGIV). In this double-blind trial each of 29 immunodeficient patients received three consecutive monthly infusions (100 or 150 mg/kg immune globulin) of one preparation before being crossed over to the other. Only 3 of 29 patients had adverse reactions when on IGIV-maltose, compared with 22 who had side-effects during infusions of IGIV (p < 0.001). Adverse reactions were recorded during 3 of 87 IGIV-maltose infusions and during 51 infusions with the maltose-free IGIV (p < 0.001). 27 patients expressed preference for IGIV-maltose. IGIV-maltose seems safe and will permit rapid infusion of large doses of immune globulin, thus improving the management of patients with antibody deficiency diseases.

Duke Scholars

Published In

Lancet

DOI

ISSN

0140-6736

Publication Date

November 29, 1980

Volume

2

Issue

8205

Start / End Page

1158 / 1159

Location

England

Related Subject Headings

  • Maltose
  • Male
  • Infusions, Parenteral
  • Immunologic Deficiency Syndromes
  • Immunoglobulins
  • Immune Sera
  • Humans
  • General & Internal Medicine
  • Female
  • Excipients
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ochs, H. D., Buckley, R. H., Pirofsky, B., Fischer, S. H., Rousell, R. H., Anderson, C. J., & Wedgwood, R. J. (1980). Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet, 2(8205), 1158–1159. https://doi.org/10.1016/s0140-6736(80)92594-5
Ochs, H. D., R. H. Buckley, B. Pirofsky, S. H. Fischer, R. H. Rousell, C. J. Anderson, and R. J. Wedgwood. “Safety and patient acceptability of intravenous immune globulin in 10% maltose.Lancet 2, no. 8205 (November 29, 1980): 1158–59. https://doi.org/10.1016/s0140-6736(80)92594-5.
Ochs HD, Buckley RH, Pirofsky B, Fischer SH, Rousell RH, Anderson CJ, et al. Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet. 1980 Nov 29;2(8205):1158–9.
Ochs, H. D., et al. “Safety and patient acceptability of intravenous immune globulin in 10% maltose.Lancet, vol. 2, no. 8205, Nov. 1980, pp. 1158–59. Pubmed, doi:10.1016/s0140-6736(80)92594-5.
Ochs HD, Buckley RH, Pirofsky B, Fischer SH, Rousell RH, Anderson CJ, Wedgwood RJ. Safety and patient acceptability of intravenous immune globulin in 10% maltose. Lancet. 1980 Nov 29;2(8205):1158–1159.
Journal cover image

Published In

Lancet

DOI

ISSN

0140-6736

Publication Date

November 29, 1980

Volume

2

Issue

8205

Start / End Page

1158 / 1159

Location

England

Related Subject Headings

  • Maltose
  • Male
  • Infusions, Parenteral
  • Immunologic Deficiency Syndromes
  • Immunoglobulins
  • Immune Sera
  • Humans
  • General & Internal Medicine
  • Female
  • Excipients